Connect with us

Mental health

Tackling women’s mental health with music and tech

Published

on

By Tuned Global

Mental health problems affect both men and women, but not in equal measure. According to the Mental Health Foundation, one in five adults has a common mental health condition: about 24 per cent of women and 15 per cent of men.

The Mind Organisation also reveals women are more likely to have suicidal thoughts and to make suicide attempts than men. So how can music therapy help?

At a recent industry event, audiences attending a session on music in the medicine and research space gained insights into the therapeutic benefits of music, such as treating conditions including dementia, Parkinson’s disease, PTSD and ADHD. 

Three experts sat down to discuss this exciting and complex space and to explore how in trying to bring these treatments to patients or the broader market, the not-so-common intersection of medtech and music surfaces a number of challenges. 

How AI can strengthen music therapies

                             Felicity Baker

Music therapy itself is not new, and therapists have been delivering such interventions in one-on-one sessions and small groups for decades.

The exciting prospect highlighted during the session was that technology and AI can now enable this at scale and with evidence-based approach. 

If more people can gain access to music treatment through technology, there is the potential to decrease medication intake, reduce healthcare costs and improve outcomes.

However, scaling these therapies does introduce new considerations and challenges that traditional clinical settings have not had to face. 

Felicity Baker is a music therapist, professor at the University of Melbourne and Founder of Matchplus.ai, a sensor-based AI solution that detects early physiological markers of agitation and delivers personalised music interventions to improve the wellbeing of people living with dementia and other cognitive conditions.

With over three decades of experience in dementia care and music therapy, Baker is leading this project at prototype stage to reduce distress, medication reliance and create a more enabling environment for individuals with cognitive decline.

Having successfully secured USD $1.3m from Google.org (the philanthropic arm of Google LLC) to develop scalable technology, Baker has become one of just 15 recipients worldwide from more than 800 applications.

“We’re using wearables to actually develop algorithms that can predict when someone is going to start wandering or is going to get up and have a fall or hit another resident in the nursing home,” she said. 

“We’ve got it down to between five and 15 minutes, so a carer or family member can anticipate that something’s going to happen.”

Baker said using AI to help preempt when to use music was one thing, but then what order the music should come in, what kind of music and how to be sensitive to the specific symptoms of people with dementia created further challenges they continue to work on.

Simone Dalla Bella, co-director of the BRAMS laboratory at the University of Montreal is conducting research focused on rhythm interventions for patients with various disorders, including Parkinson’s disease.

                             Simone Dalla Bella

The interventions include rhythmic serious games such as Beat Workers, and mobile apps such as BeatMove, developed by the start-up BeatHealth that Dalla Bella co-founded.

For example, BeatMove can adjust music tempo to help Parkinson’s patients walk more effectively. 

“Imagine that you have music in the background that you chose, and the music is going a bit faster than you, so it motivates you to run a bit faster.

“But then if you’re tired and you slow down, the music will follow you gently as if you were running or walking with a theoretical partner,” he said. 

“A clinical trial is currently ongoing in France to test a large group of patients with Parkinson’s who basically take the app outside in a park, they use it, and we are seeing beneficial effects of that kind of intervention.”

Navigating music licensing challenges

The prospect of music-powered therapy is rather inspiring and life-affirming. Providing outcomes for patients with debilitating conditions in a non-invasive way is certainly a noble cause for academics and entrepreneurs alike to take up.

However, what many might not have considered is how these medical applications acquire and manage music rights. 

Virginie Chelles, VP and Global Head of Marketing and Communications for music licensing and technology company Tuned Global, described the complexity facing these innovators.

In working with medical technology clients, Chelles highlighted that while founders deeply understand the science and tech behind their products and projects, they often have no knowledge of music industry operations.

“When it comes to us, there is a whole new industry, being the music industry which has little or no connection with the medical industry, [which in itself also] has a lot of regulation,” she said.  

In the medical music space, Tuned Global currently works with MediMusic, a UK startup that uses AI to analyse brain responses and select music for anxiety and pain management.

Companies like MediMusic are obviously performing powerful and important work, but in cases where they are not up to speed on all of the requirements to correctly licence music, they are adding layers of risk to an already compliance-heavy environment. 

                           Virginie Chelles

“They’re dealing with the legal side of medicine in being able to have it delivered in NHS Hospitals in the UK, and going for trials and all that is involved.

“There is a lot of paperwork to do there,” Chelles said. “But then, if they play the wrong track, [a] track that was not licensed, the business is in trouble.”

“[They would be looking at lawsuits], and they wouldn’t be paying the rights to the right people. There are master rights, there’s publishing rights. [So they think], ‘How do I do that? How do I find the right tracks?’.” 

Often in these kinds of apps, an AI personalisation solution will drive the selection of tracks that resonate with certain patients, so another challenge for medtech clients in knowing the extent of what other tracks they will need access to.

Companies must also consider whether their licenses permit training medical algorithms on music assets. 

“Thousands of tracks are released every day, and [if you look at what’s being produced] with AI. It’s even more,” she said. 

“Many companies don’t need millions of tracks. If you work on dementia, just working on a back catalogue, like the catalog that makes sense for these people when they were in their 20s. 

“For us, it helped us to understand what you need to license the right catalog, rather than millions of tracks, because accessing millions of tracks is a lot of money in storage and in processing.” 

Understanding music licensing early in the innovation process

For medtech companies wanting to leverage music, Chelles was direct about the challenges and decisions they face when they first approach music licensing.

A lot of consideration needs to be made about how much music they need, what kind, whether they need commercial music or production music and more. 

When MediMusic first engaged Tuned Global, these considerations presented a big challenge.

“Because licensing music is not a science. It’s not predictable, but we can definitely help,” she said. 

Elaborating further, Chelles said that companies tended to be more successful when they addressed music licensing early in development rather than treating it as an afterthought.

“It’s going to take as much time to build the music and the licensing and compliance technology as building your medical device or app or science behind it,” 

“Talk to a music expert early on, it can be us, but it can also be entertainment lawyers or licensing specialists that are going to be able to help from the beginning … to just understand what it is about.

“We can also help them to build their business case to pitch to those labels, because this can be quite strategic depending on the label and their current objectives.

“Making big pitches without understanding them or the broader environment could cost a lot of time and money if they don’t sign you up right away.

“Being able to demonstrate and communicate value in this industry on the industry’s terms is really important for success, so if you can work with people that have these relationships and can engage with them it’s very helpful.” 

Working with an established music technology company can help medtech startups navigate label negotiations. Labels recognise that companies already working with licensing specialists have typically secured funding and understand the commercial requirements.

“[The labels are] like, okay, they are legit, because if Tuned Global can work with them, they already have the funding and they understand what they’re doing,” Chelles said. 

Securing licensing agreements is only the first step. Companies then need backend technology to access the actual tracks.

Tuned Global maintains 190 million tracks, with the catalog growing daily.

Companies must negotiate separately with both master rights holders (the record labels) and publishers who represent musicians and writers.

Commercialising research and innovation

Neither researcher came from a background that prepared them for music industry negotiations.

Despite publishing in The Lancet and Nature and securing major medical research grants, Baker found music licensing remained unfamiliar territory.

Dalla Bella received more than $USD 3.5m in European research funding but similarly had no training in navigating music rights.

Startup activity at universities is growing, but this has not always been the case.

Baker noted that while the institutions themselves were very supportive and really wanted to push research innovations into the market, there still exists some commercialisation stigmas among some researchers. 

“For some researchers, commercialising your research is kind of almost like a dirty word.

“To them it’s like you’re not being true to the science if you want to actually make a company and do something with this,” she said. 

Dalla Bella described how moving from pure research into commercial applications required stepping outside his comfort zone.

“Sometimes in science, we’re very closed, right?

“We do work just in science, in our niche, we are happy with what we do, but then you have to go beyond your comfort zone to start to work with engineers and start to work with a startup company,” he said.

“[I’ve seen for a lot of people] it took time to build this collaboration, this common language, and to be able to work together. After a certain amount of time, you discover the real potential of doing that.”

The future of tech powered music therapies

The medical music technology sector is an exciting and expanding space.

As more innovators enter the industry, the intersection between healthcare regulation and music licensing will likely require more standardised frameworks and understanding of the complexities so they aren’t bogged down or exposed to complications that could cut their journey to provide care short.

For now, companies navigating both industries must build relationships with experts in each domain.

The medical science may be groundbreaking, but without proper music licensing infrastructure, therapeutic applications cannot reach patients or compensate the artists whose work makes treatment possible.

About Tuned Global

Tuned Global is the leading data-driven cloud and software platform that empowers businesses to integrate commercial music into their apps or launch complete streaming experiences using advanced APIs, real-time analytics, licensing solutions, and customisable white-label apps.

Our turnkey solutions for music, audio, and video — coupled with a broad ecosystem of third-party music tech integrations — make us the most comprehensive platform for powering any digital music project. We streamline complexities in licensing, rights management, and content delivery, enabling rapid innovation and bringing new ideas to life.

Since 2011, we’ve supported 40+ companies in 70+ countries — across telecom, fitness, media, aviation, and more — to deliver innovative music experiences faster and more cost-effectively.

For more information, visit www.tunedglobal.com.

Mental health

Women more likely than men to get health advice from influencers, study finds

Published

on

Young women are more likely than young men to get health and wellness information from social media influencers, a US survey has found.

Among adults aged 18 to 29, 57 per cent of women said they received health and wellness information from influencers, compared with 47 per cent of men.

The Pew Research Center study surveyed 5,023 US adults and examined how young people consume health and wellness content online.

Local university students said influencer content frequently appeared in their social media feeds.

Kabija Koroma, a local university student, said: “It’s more exercise stuff, more like protein and like meals and like how to get ready and like the outfits of the day of videos on TikTok or lately. My favourite ones.”

About 51 per cent of women under 30 said they often consumed influencer content focused on beauty and personal appearance, compared with 18 per cent of men.

The study also found that 21 per cent of women often saw content about therapies outside mainstream medicine, compared with 10 per cent of men.

At least one-third of both young women and young men often encountered influencer content about mental health and weight loss. Around half or more of both groups regularly saw fitness-related content.

Another local university student, Ania Davis, said: “I see a lot like how to meal prep and how to get your morning started. Affirmations stuff. But I do also ask the adults around me because sometimes the internet is not right.”

Researchers also looked at why young adults sought health and wellness information from influencers.

About 51 per cent of young women said they watched the content because they wanted to change their health or lifestyle.

Women were also more likely than men to say they enjoyed hearing from people who shared their background or beliefs, at 23 per cent compared with 14 per cent.

Nineteen per cent of young women said they used influencer content to learn about topics they did not want to ask their doctors about, compared with 10 per cent of young men.

Despite regularly using social media, some students said they did not rely solely on influencer content when making decisions about their health and wellness.

Koroma said: “I’m always on TikTok 24/7 and Instagram, but I also like to ask people older than me because I don’t know everything.”

Continue Reading

Pregnancy

UK study aims to transform maternity care for high-risk pregnancies

Published

on

A new UK study aims to improve maternity care for pregnant women living with multiple long-term health conditions.

The three-year project, led by the University of Aberdeen and Birmingham City University, brings together experts from academia and the NHS, including King’s College London, the University of Birmingham, Manchester University, Barts Health NHS Trust, Newcastle-upon-Tyne NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust.

The research is supported by a £1.3m award from the National Institute for Health and Care Research (NIHR), with £70,000 of the funding going to King’s College London.

Recent figures show that more than 80 women die each year in the UK due to complications arising from pregnancy, while more than one in six pregnant women are living with multiple long-term conditions such as diabetes, high blood pressure, heart disease and mental health disorders.

These conditions are becoming increasingly common and are considered an important contributor to poor maternal outcomes.

There are currently no defined care requirements for pregnant women living with more than one long-term health condition.

Women living with multiple conditions can face changes to medication, disjointed care from multiple teams, conflicting advice between healthcare professionals and a lack of appropriate follow-up for their health conditions after birth.

Pregnant women with multiple long-term health conditions are at twice the risk of preterm birth and nine times more likely to die during pregnancy than those without these health complications.

Researchers will develop a “care bundle”, a package of evidence-led care designed to guide safe maternity care for women living with multiple long-term health conditions throughout pregnancy, birth and the postnatal period.

At King’s, Professor Krishnarajah Nirantharakumar and Professor Jane Sandall will be co-investigators on the project, contributing expertise in implementation research and continuity of maternity models of care. Zoe Vowles, an NIHR-funded midwife PhD student, will contribute expertise from her research into the contribution of midwifery to care for women with multiple long-term health conditions.

Sandall, professor of social science and women’s health at King’s College London, said: “Too many women living with more than one long-term health condition are falling through the gaps between different parts of the health system during pregnancy, when they most need coordinated support. This research will bring together expertise from across maternity and specialist care to build a care bundle that gives women and health professionals clear, consistent guidance, before, during and after birth.”

Nirantharakumar, clinical professor of public health and health data science at King’s College London, said: “Our MRC-funded MuM-PreDiCT programme worked directly with women living with multiple long-term conditions and with maternity clinicians to identify the elements of care that matter most in pregnancy. This award takes those elements and builds them into a care bundle that can be tested and delivered in the NHS.”

Over three years, the team will be led by Dr Mairead Black, clinical reader in obstetrics at the University of Aberdeen and honorary consultant obstetrician at NHS Grampian. It will address the challenges these women face and create a package of care aimed at reducing the risks they encounter in pregnancy.

The care bundle will include guidance on medication management, communication between healthcare teams, midwifery care and postnatal handovers. Researchers will also work with people with lived experience of maternity care to help shape and test it.

The researchers hope the project will provide an evidence-led care bundle specifically designed for women living with multiple long-term health conditions and, for the first time, clear guidance to support their complex needs throughout pregnancy and beyond.

Continue Reading

Mental health

PMDD after SSRIs or hormones: Why the brain may be the missing treatment target

Published

on

Prepared for Femtech World by Dr Emilė Radytė, neuroscientist and co-founder and CEO of Samphire Neuroscience

The short answer

Premenstrual dysphoric disorder (PMDD) does not usually result from abnormal hormone levels.

Research suggests that the brain can respond differently to expected changes in estrogen, progesterone, and the progesterone metabolite allopregnanolone.

This helps explain why blood tests can look typical while a person’s experiences remain severe. It also gives researchers a clear reason to study nervous-system treatments alongside selective serotonin reuptake inhibitors (SSRIs), hormonal treatment, and psychological care.

Why can expected hormone changes cause severe PMDD experiences?

Hormones act as signals. They interact with receptors throughout the brain and influence networks involved in mood, stress, sleep, and emotional regulation.

Two people can have similar hormonal patterns and experience those signals in different ways.

Hantsoo and Epperson (2020) reviewed evidence that PMDD involves an altered response to changing levels of allopregnanolone, which modulates gamma-aminobutyric acid type A (GABA-A) receptors. GABA helps regulate neural activity and the stress response.

In PMDD, the issue may lie in the brain’s adaptation to allopregnanolone fluctuations across the menstrual cycle.

Experimental research supports this sensitivity model. Suppressing ovarian hormone fluctuations can reduce PMDD experiences in susceptible participants, while reintroducing physiologic concentrations can bring them back.

Researchers therefore describe PMDD as a disorder of sensitivity to hormonal change, while recognizing that no single pathway explains every case.

Do normal hormone test results rule out PMDD?

No. A blood test shows whether a hormone concentration falls within an expected range at one point in time.

It cannot show how a person’s brain responds to that signal across the cycle.

Clinicians diagnose PMDD by its timing and impact, using prospective daily ratings across menstrual cycles.

The American College of Obstetricians and Gynecologists (ACOG) recognises PMDD as part of a spectrum of premenstrual disorders and recommends an individualised, multimodal approach.

Which treatments have evidence for PMDD?

ACOG’s 2023 clinical practice guideline includes hormonal and nonhormonal medicines, psychological counseling, exercise, nutritional approaches, patient education, and surgery for selected cases.

SSRIs can work faster in PMDD than they often do in major depression. Hormonal approaches can suppress ovulation or stabilize fluctuations for some patients.

No treatment works for every person. Some patients do not improve, cannot tolerate side effects, have contraindications, or prefer another route.

When that happens, clinicians and researchers need to ask which part of the biological pathway still drives the condition.

Could brain stimulation treat PMDD?

Noninvasive brain stimulation offers a plausible research direction because it can influence neural networks involved in mood regulation.

Evidence from depression cannot establish that it works for PMDD.

Researchers need PMDD-specific randomised trials that measure experiences across the cycle and report safety, adherence, and clinically meaningful outcomes.

The distinction matters. A coherent mechanism creates a hypothesis. Only indication-specific clinical evidence can establish efficacy.

Key takeaways

  • PMDD can occur with hormone levels that fall within expected ranges.
  • Research points to altered brain sensitivity to hormonal change, including allopregnanolone fluctuations.
  • SSRIs and hormonal approaches remain evidence-based options, often as part of multimodal care.
  • Brain stimulation is a research target for PMDD, not a conclusion that can be borrowed from depression studies.

Learn more at https://www.samphireneuro.com/en-us/pmdd

Sources:

Hantsoo and Epperson (2020), Allopregnanolone in premenstrual dysphoric disorder.

American College of Obstetricians and Gynecologists (2023), Management of premenstrual disorders.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.